- Home
- Companies
- canada alberta
- vaccine based
Refine by
Vaccine Based Suppliers Serving Alberta
27 companies found
based inIrvine, CALIFORNIA (USA)
Since 1994, Zymo Research has been led by a vision to have a positive impact in the biomedical field and to contribute to the greater good of humanity. Our innovative sample collection reagents, kits and devices have been used all over the World; ...
based inChatham, NEW JERSEY (USA)
Tonix is a clinical-stage biopharmaceutical company focused on developing novel therapies and vaccines to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. At Tonix, we are focused on ...
TNX-1850 is the planned new version of the TNX-1800 vaccine that encodes spike protein from SARS-CoV-2 BA.2 ...
based inBerlin, GERMANY
ProBioGen AG is a renowned Contract Development and Manufacturing Organization (CDMO) and technology provider. We perform cell line engineering, process development, and GMP manufacturing of biopharmaceuticals for clients in biotech and pharma. We ...
All our proprietary cell lines are characterized by excellent productivity, safety, and stability. They are used in the industrial production of virus-based vaccines or recombinant proteins and are suitable for the ...
based inHangzhou City, CHINA
Cnpair Biotech Co., Ltd. is a professional provider which concentrates on IVD core materials, including antibodies and proteins, and we are dedicated to developing and delivering highly competitive antibodies and proteins with outstanding ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
To accelerate the development of cancer immunotherapy, it is essential to systematically identify tumor antigens that are truly tumor-specific, patient-shared, stably expressed (i. e., cloned) and immunogenic in all malignant cells. ...
based inMaidenhead, UNITED KINGDOM
As a global leader in influenza protection, CSL Seqirus has one of the broadest influenza vaccine portfolios in the world. In the Asia Pacific region we also provide access to a wide range of vaccines and specialty medicines that meet unique, local ...
As a global leader in influenza protection, Seqirus has one of the broadest influenza vaccine portfolios in the world. In the Asia Pacific region we also provide access to a wide range of vaccines and specialty medicines that meet unique, local ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
based inNew York, NEW YORK (USA)
Founded in 1985, we are a private, closely held company passionate about delivering science-driven innovation with platform capabilities. Our scientific achievements include the world’s first peptide-based diagnostic test and first fully synthetic ...
Development of vaccines for human health based on a synthetic peptide platform, spanning therapeutic areas such as neurology, allergy, and infectious ...
based inSchlieren, SWITZERLAND
Virometix is a clinical stage biotech company pioneering a new class of synthetic vaccines to tackle infectious diseases and cancer. Our structure-based vaccines are designed to direct a precise, robust and sustained immune response. With a ...
Effective antigen delivery and a strong and durable response is the basis for successful cancer vaccines. The SVLP approach, with its modular and flexible design, the inherent adjuvant properties and other immune system activators, ...
based inShirley, NEW YORK (USA)
CD BioSciences is a leading customer-focused biotechnology company founded in New York. Virus-like particles (VLPs) constructed on plant-based platforms can be produced on a large scale as plants can be grown cheaply and efficiently without the need ...
based inAbingdon, UNITED KINGDOM
Thermally Stable Needle Free Solid Dose Vaccines. Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax technologies. These diseases affect millions of ...
based inCampbell River, BRITISH COLUMBIA (CANADA)
Fuerste Vaccination Services Corp prides itself on being progressive in areas of Crew Health and Safety, Fish Health, Personal Management, Equipment Management and strong relations with Hatchery Management and Fish Health Staff. Our consistent ...
based inAuburn, ALASKA (USA)
SiO2 Materials Science is focused on three core segments: Pharmaceuticals, Molecular Diagnostics, and Consumer Healthcare. In the pharma segment, we solve more than 30 problems including some of the most challenging related to drug stability, drug ...
based inREDWOOD CITY, CALIFORNIA (USA)
EnGen Bio is developing a therapy and vaccine to provide lifetime immunity to Type A flu. We´ve discovered influenza´s ¨Achille´s heel¨ Unlike conventional flu vaccines, which are generally hemagglutinin or whole-virus based, our vaccine targets a ...
based inShirley, NEW YORK (USA)
CD BioSciences, a New York-based company, is currently developing a silicon-based high throughput DNA synthesis method. Our htDNA-chip technology platform makes it possible to synthesize DNA with high throughput, efficiency and precision. It expands ...
The nucleic acid vaccines development process is mainly divided into the following steps: isolation and screening of pathogenic genes, sequencing of pathogenic genes, targeted cloning of antigen genes, the introduction of recombinant genes into ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to ...
based inHercules, CALIFORNIA (USA)
Bio-Rad is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for 70 years, our products ...
The dengue virus (DENV), first isolated in 1943, is assigned to the family Flaviviridae, genus Flavivirus. It has four serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) and transmission to humans occurs via the Aedes mosquito, mainly Aedes aegypti. Its ...
based inSt-Jean, QUEBEC (CANADA)
We are an innovative pharmaceutical company determined to improve the lige of people with allergy. We have developed our biotechnology with you in mind. How could we turn on sharp insights on allergy and precision medicine into a better life for ...
ANGANY is joining the COVID-19 effort with its promising novel vaccination technology. The unprecedented social and economic upset caused by the pandemic called for social responsibility. ANGANY’s entire team pitched in to join the fight! The ...
based inDallas, TEXAS (USA)
Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Headquartered in Dallas, TX, with operations in the United States, Latin America, Europe and Asia, the company’s proprietary technology ...
Employs a “multitope” approach to neutralizing the SARS-CoV-2 virus, eliciting a well-balanced B and T-cell response against multiple viral epitopes. Phase 1 and Phase 2 trials of UB-612 have shown UB-612 to be well tolerated, with no ...
based inOxford, UNITED KINGDOM
The Native Antigen Company has developed a proprietary HEK293 mammalian expression system (VirtuE) for expression of recombinant proteins. The Native Antigen Company has rapidly become one of the world’s leading suppliers of infectious disease ...
Recombinant Chikungunya Virus-Like Particles produced in mammalian HEK293 cells. Chikungunya structural proteins are transiently expressed to form a particle comprising E1, E2 and capsid protein, without the non-structural proteins or genome. ...
